[Cardioxan: prevention of anthracycline-related cardiotoxicity].
Gershanovich
M L
ML
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000818:Animals; D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002614:Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006331:Heart Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007942:Leukemia, Experimental / Q000188:drug therapy; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011929:Razoxane / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D018943:Anthracyclines; D002316:Cardiotonic Agents; D002317:Cardiovascular Agents; D002614:Chelating Agents; D007166:Immunosuppressive Agents; D011929:Razoxane; D004317:Doxorubicin